Evaluation of dAroLutamide Addition to anDrogen Deprivation Therapy and radIatioN Therapy in Newly Diagnosed Prostate Cancer With Pelvic Lymph Nodes Metastases
Latest Information Update: 03 Oct 2024
At a glance
- Drugs Darolutamide (Primary)
- Indications Adenocarcinoma; Cancer metastases; Prostate cancer
- Focus Therapeutic Use
- Acronyms ALADDIN
- 04 Jun 2024 Trial design presented at the 60th Annual Meeting of the American Society of Clinical Oncology.
- 11 Mar 2024 Status changed from not yet recruiting to recruiting.
- 10 Feb 2022 Planned initiation date changed from 1 Jan 2022 to 1 Apr 2022.